Commercialisation is at full-pace for Orthocell (ASX:OCC) in the US$1.6 billion nerve repair market, as the company pushes ahead with the rollout of its flagship product, Remplir™, in the US.
Ten surgeries have now been completed in the US, with early adoption tracking in line with Orthocell’s strategy.
In line with that, 36 applications have been lodged with hospital Value Assessment Committees — which review a product’s safety, clinical benefits, and cost-effectiveness before approving its use. So far, three hospitals have given the green light.
To support the rollout, Orthocell has shipped 4,000 units of Remplir from its Western Australian facility to its US logistics partner, Uniphar, and has strengthened its American team with two new hires.
Orthocell's CEO, Paul Anderson, said: "Our network of distributors remains an important avenue to market and they have been instrumental in identifying key hospitals for us to target VAC approvals. This is the next important step for us in order to achieve more widespread adoption of Remplir, which in turn will drive revenue generation for Orthocell.”
The company says momentum is building, and growth is on track to match its global commercialisation plans.
#ASX #Orthocell #OCC #MedicalTechnology #NerveRepair #USMarket #HealthcareInnovation #Commercialisation #MedicalDevices #Remplir